trans-tert-butyl 3-hydroxy-3,4-dimethylpiperidine-1-carboxylate

Catalog No. :
ACODLE934
CAS No. :
1932032-51-3
Molecular Formula :
C12H23NO3
Molecular Weight :
229.32

IUPAC Name:tert-butyl (3S,4S)-3-hydroxy-3,4-dimethylpiperidine-1-carboxylate

trans-tert-butyl 3-hydroxy-3,4-dimethylpiperidine-1-carboxylate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
250mg97%$626.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Nametrans-tert-butyl 3-hydroxy-3,4-dimethylpiperidine-1-carboxylate
IUPAC Nametert-butyl (3S,4S)-3-hydroxy-3,4-dimethylpiperidine-1-carboxylate
MDL No.MFCD28119208
Molecular FormulaC12H23NO3
Molecular Weight229.32
SMILESC[C@H]1CCN(C(=O)OC(C)(C)C)C[C@@]1(C)O
InChI KeyFBDBUQWAAYRPBZ-JOYOIKCWSA-N
SynonymTrans-Tert-Butyl 3-Hydroxy-3,4-Dimethylpiperidine-1-Carboxylate(WX641184);TRANS-TERT-BUTYL 3-HYDROXY-3,4-DIMETHYLPIPERIDINE-1-CARBOXYLATE;TRANS-TERT-BUTYL 3-HYDROXY- 3, 4-DIMETHYLPIPERIDINE-l-CARBOXYLATE;1-Piperidinecarboxylic acid, 3-hydroxy-3,4-dimethyl-, 1,1-dimethylethyl ester, (3S,4R)-
CAS No.1932032-51-3

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P280-P301+P312-P302+P352-P305+P351+P338

Synthetic Route by SureRoute

1. ACODLE934 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACODLE934 route product structure diagram
    ACODLE9341932032-51-3
Inquiry

2. ACODLE934 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACODLE934 route product structure diagram
    ACODLE9341932032-51-3
Inquiry

Comments (0)